MEDCL Stock Overview
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.16 |
| 52 Week High | €17.50 |
| 52 Week Low | €5.25 |
| Beta | 1.04 |
| 1 Month Change | 19.75% |
| 3 Month Change | 62.84% |
| 1 Year Change | 126.61% |
| 3 Year Change | 40.37% |
| 5 Year Change | 118.44% |
| Change since IPO | 106.26% |
Recent News & Updates
Recent updates
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Shareholder Returns
| MEDCL | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 7.5% | -1.5% | -1.3% |
| 1Y | 126.6% | -4.7% | 7.0% |
Return vs Industry: MEDCL exceeded the French Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: MEDCL exceeded the French Market which returned 6.8% over the past year.
Price Volatility
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: MEDCL's share price has been volatile over the past 3 months.
Volatility Over Time: MEDCL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 138 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
| MEDCL fundamental statistics | |
|---|---|
| Market cap | €440.48m |
| Earnings (TTM) | -€26.42m |
| Revenue (TTM) | €14.13m |
31.2x
P/S Ratio-16.7x
P/E RatioIs MEDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDCL income statement (TTM) | |
|---|---|
| Revenue | €14.13m |
| Cost of Revenue | €0 |
| Gross Profit | €14.13m |
| Other Expenses | €40.55m |
| Earnings | -€26.42m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jun 10, 2024
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -187.04% |
| Debt/Equity Ratio | -245.0% |
How did MEDCL perform over the long term?
See historical performance and comparison